Clinical trials: Hypertension, Pulmonary
Pulmonary Arterial Hypertension
A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).
Study KER-012-A201 is Phase 2, double-blind, randomized, placebo-controlled study to determine the efficacy and safety of KER-012 compared to Placebo in adults with PAH (WHO Group 1 PH) on stable background PAH therapy.
- Trial name
- NCT05975905
- Testing
- Dose A KER-012, Dose B KER-012, Dose C KER-012
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 113 people
- Sponsor
- Keros Therapeutics, Inc.
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
This prospective study is a multi-center early feasibility study assessing the safety and performance of the Aria CV Pulmonary Hypertension System in patients with pulmonary hypertension and right heart dysfunction.
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, Right Heart Dysfunction
- Trial name
- ASPIRE PH (NCT04555161)
- Testing
- Aria CV Pulmonary Hypertension System
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- Aria CV, Inc
Pulmonary Hypertension, Interstitial Lung Disease
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-211 (NCT05176951) and other lead-in studies of TPIP in participants with…
- Trial name
- NCT05649722
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 22 sites in Argentina, Australia and 5 more
- Volunteers
- 31 people
- Sponsor
- Insmed Incorporated
Pulmonary Arterial Hypertension (PAH)
A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag
This study will look at safety and tolerability of LIQ861 (treprostinil) inhalation powder in adults with pulmonary arterial hypertension (PAH, WHO Group 1) who switch from selexipag, a medicine taken by mouth, to treprostinil, a…
- Trial name
- NCT07759804
- Testing
- LIQ861 (treprostinil) inhalation powder
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Liquidia Technologies, Inc.
Systemic Sclerosis, Pulmonary Hypertension
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package; i.e.
- Trial name
- NCT02246348
- Testing
- Doppler ultrasound
- Where
- Israel
- Volunteers
- 5 people
- Sponsor
- Echosense Ltd.
Pulmonary Hypertension, Interstitial Lung Disease
A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases
- Trial name
- NCT07816185
- Testing
- Mosliciguat, Dry Powder Inhaler
- Where
- 3 sites in United States
- Volunteers
- 376 people
- Sponsor
- Pulmovant, Inc.
Pulmonary Arterial Hypertension
Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.
- Trial name
- NCT00423748
- Testing
- ambrisentan
- Volunteers
- 186 people
- Sponsor
- Gilead Sciences
Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
- Trial name
- Re-PHIRE (NCT05737940)
- Testing
- AZD3427
- Where
- 60 sites in United States, Austria and 12 more
- Volunteers
- 260 people
- Sponsor
- AstraZeneca
Hypertension, Pulmonary
Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension
The main aim of the observational VENTASTEP study was to investigate the association between changes in clinical outcome measures and changes in device outcome measures in PAH patients using the new Breelib nebulizer in a real…
- Trial name
- VENTASTEP (NCT03293407)
- Testing
- Iloprost (Ventavis, BAYQ6256), Breelib nebulizer
- Where
- Germany
- Volunteers
- 31 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension
This is a Phase 1B, randomized, participant- and investigator-blinded, placebo-controlled, multi-center clinical trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and biomarkers of inhaled GB002 in…
- Trial name
- PAH (NCT03926793)
- Testing
- GB002, Generic Dry Powder Inhaler
- Where
- 14 sites in United States, United Kingdom
- Volunteers
- 8 people
- Sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Pulmonary Arterial Hypertension
Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome
Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndrome.
- Trial name
- MAESTRO-OL (NCT01739400)
- Testing
- Macitentan 10 mg tablet, once daily.
- Where
- 51 sites in United States, Austria and 17 more
- Volunteers
- 217 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)
The purpose of the study is to document the effect of first line dual oral combination therapy with macitentan 10mg and tadalafil 40mg on pulmonary vascular resistance (PVR) in treatment-naïve patients with newly diagnosed…
- Trial name
- OPTIMA (NCT02968901)
- Testing
- macitentan, tadalafil
- Where
- 18 sites in France
- Volunteers
- 46 people
- Sponsor
- Actelion
Pulmonary Hypertension
Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)
The primary objectives of this study are to assess the safety/tolerability and efficacy (by evaluating changes in pulmonary vascular resistance [PVR] and pulmonary blood volume [PBV]) of frespaciguat in participants with…
- Trial name
- NCT04370873
- Testing
- Frespaciguat
- Where
- 9 sites in United States, Israel and 1 more
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
Eisenmenger Quality Enhancement Research Initiative
Eisenmenger Quality Enhancement Research Initiative (QuERI) is a multi-center, observational, US-based longitudinal program, with enrollment of consecutive Eisenmenger patients who meet enrollment.
- Trial name
- ES-QuERI (NCT01623492)
- Testing
- Subjects with diagnosis of Eisenmenger Syndrome
- Volunteers
- 193 people
- Sponsor
- Actelion
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
This open-label study will evaluate the safety of continued therapy with inhaled treprostinil in participants who have completed Study RIN-PH-304 (NCT03496623).
- Trial name
- PERFECT OLE (NCT03794583)
- Testing
- Inhaled treprostinil solution
- Where
- 32 sites in United States, Israel and 1 more
- Volunteers
- 41 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Adult Congenital Heart Disease Registry (QuERI)
Multi-center, observational, U.S.-based longitudinal program. Data will be collected prospectively for 3 years. Individual physician feedback will be provided on data collected with the purpose of improving the management of…
- Trial name
- NCT01659411
- Testing
- Observational
- Volunteers
- 217 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
As sitaxsentan is the agent most highly selective for ETA (Endothelin Type A (receptor)), and does not significantly impact sildenafil pharmacokinetics the combination of most promise for pulmonary arterial hypertension (PAH)…
- Trial name
- NCT00796510
- Testing
- Sitaxsentan, Sitaxsentan and Sildenafil
- Where
- 3 sites in United States, Romania and 1 more
- Volunteers
- 3 people
- Sponsor
- Pfizer
Pulmonary Hypertension
Preliminary Human Trials of F230 Tablets
F230 is a new Class 1 chemical drug jointly developed by Beijing Contini Pharmaceutical Co., Ltd. for the treatment of pulmonary hypertension (Notification number: 2024LP01242, 2024LP01243).
- Trial name
- NCT06899815
- Testing
- F230 tablets
- Where
- China
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Pulmonary Arterial Hypertension
A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)
Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that carry blood from the heart to the lungs. PAH occurs when the openings in the blood vessels of the lungs get smaller and smaller.
- Trial name
- ROAR (NCT04813926)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 50 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Safety and Efficacy of Inhaled Treprostinil in Patients With PAH
To evaluate the effect of inhaled treprostinil compared to placebo on exercise capacity and time to clinical worsening.
- Trial name
- INTREPID (NCT01557647)
- Testing
- Inhaled treprostinil
- Sponsor
- United Therapeutics